Cancer Institute– A national cancer institute
designated cancer center
Profile http://med.stanford.edu/profiles/Frederick_Chin/ Email this profile Generate Profile PDF
Portrait View Larger

Frederick T. Chin, Ph.D.

Academic Appointments

Key Documents

Contact Information

  • Academic Offices
    Personal Information
    Email Tel (650) 725-4182
    Alternate Contact
    Donna Niernberger Administrative Associate Tel Work (650)736-0449

Professional Overview

Administrative Appointments

  • Head, Cyclotron Radiochemistry, Stanford University School of Medicine, Department of Radiology, Stanford, CA USA (2005 - present)
  • Member, Radioactive Drug Research Committee, Stanford University, Stanford, CA USA (2005 - present)
  • Member, Administrative Panel on Radiological Safety, Stanford University, Stanford, CA USA (2009 - present)
  • Member, Non-Human Use Radiation Safety Committee, Stanford University, Stanford, CA USA (2011 - present)

Honors and Awards

  • NIH Fellow Award for Research Excellence, National Institutes of Health, Bethesda, MD USA (2003, 2004)
  • NIH Intramural Research Fellowship, National Institutes of Health, Bethesda, MD USA (2002-2005)
  • LBNL Research Fellowship, Lawrence Berkeley National Laboratory, Berkeley, CA USA (2001-2002)
  • Physical Scientist Research Award, Indiana University School of Medicine, Department of Radiology, Indianapolis, IN USA (1998)
  • "Excellence in Teaching" Award, Indiana University - Purdue University at Indianapolis, Indianapolis, IN USA (1998)
  • Phi Beta Kappa, Indiana University, Bloomington, IN USA (1990)

Professional Education

Ph.D.: Purdue University, W. Lafayette, IN, Organic Chemistry/Radiochemistry (2000)
B.S. with Honors: Indiana University, Bloomington, IN, Chemistry (1991)

Graduate & Fellowship Program Affiliations

Scientific Focus

Current Research Interests

Our group's primary objectives are:

1) Novel radioligand and radiotracer development.
We will develop novel PET (Positron Emission Tomography) imaging agents with MIPS and Stanford faculty as well as other outside collaborations including academia and pharmaceutical industry. Although my personal research interests will be to discover and design of candidate probes that target molecular targets in the brain, our group focus will primarily be on cancer biology and gene therapy. In conjunction with our state-of-the-art imaging facility, promising candidates will be evaluated by PET imaging in small animals and primates. Successful radioligands and/or radiotracers will be extended towards future human clinical applications.

2) Designing new radiolabeling techniques and methodologies.
We will aim to design new radiolabeling techniques and methodologies that may have utility for future radiopharmaceutical development in our lab and the general radiochemistry community.

3) Radiochemistry production of routine clinical tracers.
Since we also have many interests with many Stanford faculty and outside collaborators, our efforts will also include the routine radiochemistry production of many existing radiotracers for human and non-human use. Our routine clinical tracers will be synthesized in custom-made or commercial synthetic modules (i.e. GE TRACERlab modules) housed in lead-shielded cells and be distributed manually or automatically (i.e. Comecer Dorothea) to our imagers.

Clinical Trials

Publications

CAP profiles with similar publication topics
Publication tag cloud

Publication Topics

close
View All 31

Stanford Medicine Resources:

Footer Links: